Analyst's Viewpoint About Viacom, Inc. (VIAB), Boston Scientific Corporation (BSX)

Cornelia Mascio
Settembre 25, 2017

Its down 0.40, from 1.32 in 2017Q1. At the time of writing, Shares the company recently traded 46.67% away 52-week low and noted price movement -1.87% away from the 52-week high level. 56 funds opened positions while 165 raised stakes. It is positive, as 41 investors sold Boston Scientific Corporation shares while 173 reduced holdings. During the same period in the prior year, the company posted $0.27 earnings per share.

The EPS this year for Boston Scientific Corporation, BSX is 0.57 following the EPC growth of next year of 11.62%. RBC Capital Markets maintained the shares of BSX in report on Monday, July 10 with "Buy" rating. Pggm Investments owns 232,120 shares for 0.03% of their portfolio.

Icon Advisers Inc increased Mfs Invt Grade Mun Tr Sh Ben I (NYSE:CXH) stake by 68,531 shares to 291,627 valued at $2.96 million in 2017Q2. The volume of VIAB witnessed a shift from 3.98 million shares, based on a 50-day average, to 5.28 million shares. Pura Vida Investments Llc, a New York-based fund reported 420,546 shares. Art Advsrs Limited Liability Corp holds 0.04% or 25,975 shares. Allstate Corporation holds 0.09% or 64,201 shares. Livforsakringsbolaget Skandia Omsesidigt has 0.07% invested in Boston Scientific Corporation (NYSE:BSX). FIL Ltd owned about 0.09% of Boston Scientific Corporation as of its most recent SEC filing. Boston Ltd Co has invested 0.13% in Tutor Perini Corp (NYSE:TPC). 1 equity analyst has recommended the share with a sell recommendation, five have issued a hold recommendation, thirteen has issued a buy recommendation and 1 has given a strong buy recommendation to the firms shares. Volatility allows the investors to understand the amount of uncertainty or risk regarding the size of the changes over a stock's value. 13,562 shares were sold by Pierce David A, worth $379,736 on Friday, June 9. Appaloosa Lp now owns 2,264,900 shares valued at $62,783,000. Over the last three months, insiders sold 275,257 shares of company stock valued at $7,512,394. Moreover, Adirondack Research & Management Inc. has 1.82% invested in the company for 144,914 shares. The company has market capitalization of $39.59B. The stock declined 0.76% or $0.22 reaching $28.62 per share. About 111,408 shares traded.

Boston Scientific Corporation (NYSE:BSX) last issued its quarterly earnings data on Thursday, July 27th. It has outperformed by 2.42% the S&P500. Capital Impact Advisors Llc owns 38,036 shares or 0.71% of their United States portfolio. The total value of its holdings increased 10,928.5%. Analysts have placed a $30.98 price target on Boston Scientific Corporation, suggesting a 7.72% gain from recent close. They expect $0.31 EPS, up 14.81 % or $0.04 from last year's $0.27 per share. BSX's profit would be $425.40M giving it 23.27 P/E if the $0.31 EPS is correct. On average, equities analysts forecast that Boston Scientific Corporation will post $1.26 EPS for the current fiscal year. Guardian Life Insurance of America increased its position in stocks of Boston Scientific Corporation by 0.9% during the Q1.

Boston Scientific Corporation (NYSE:BSX) has risen 19.12% since September 23, 2016 and is uptrending.

The consensus recommendation, according to Zacks Investment research, is 1.53. Therefore 78% are positive. The Netherlands-based Pggm Invs has invested 0.03% in Boston Scientific Corporation (NYSE:BSX). Hanson Mcclain has invested 0% in Boston Scientific Corporation (NYSE:BSX). The stock of Rheinmetall AG (ETR:RHM) has "Buy" rating given on Thursday, August 18 by Bankhaus Lampe. Royal Bank Of Canada reiterated a "buy" recommendation and fixed a $31.00 target price on the stock of Boston Scientific Corporation in a study report published on Fri, Sep 1st. On Thursday, October 29 the stock rating was maintained by FinnCap with "Corporate". Boston Scientific Corporation has a 52 week low of $19.67 and a 52 week high of $29.40. Needham has "Buy" rating and $21 target.

Viacom, Inc. has a beta of 1.09, offering the possibility of a higher rate of return, but also posing more risk. Boston Scientific Corporation now has a average recommendation of "Buy" and a consensus price objective of $29.88. Wedbush has "Neutral" rating and $25 target. The rating was initiated by KeyBanc Capital Markets on Friday, January 27 with "Sector Weight". The stock has "Buy" rating by Standpoint Research on Monday, April 11. BMO Capital Markets maintained the shares of BSX in report on Thursday, August 31 with "Buy" rating.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE